ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.13. The firm had revenue of $165.20 million during the quarter, compared to analysts’ expectations of $163.86 million. ACADIA Pharmaceuticals had a negative return on equity of 27.77% and a negative net margin of 20.11%. The firm’s quarterly revenue was up 22.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.21) EPS. On average, analysts expect ACADIA Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
ACADIA Pharmaceuticals Price Performance
Shares of NASDAQ ACAD opened at $22.59 on Thursday. The stock has a market capitalization of $3.70 billion, a P/E ratio of -32.74 and a beta of 0.65. ACADIA Pharmaceuticals has a 1-year low of $13.73 and a 1-year high of $33.99. The business has a fifty day moving average price of $24.89 and a 200 day moving average price of $24.62.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on ACADIA Pharmaceuticals
Insider Buying and Selling
In related news, EVP Austin D. Kim sold 16,369 shares of the firm’s stock in a transaction dated Friday, October 6th. The stock was sold at an average price of $21.96, for a total transaction of $359,463.24. Following the sale, the executive vice president now directly owns 45,857 shares of the company’s stock, valued at $1,007,019.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other ACADIA Pharmaceuticals news, EVP Austin D. Kim sold 16,369 shares of the firm’s stock in a transaction that occurred on Friday, October 6th. The stock was sold at an average price of $21.96, for a total value of $359,463.24. Following the sale, the executive vice president now directly owns 45,857 shares of the company’s stock, valued at $1,007,019.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Stephen Davis sold 51,563 shares of the firm’s stock in a transaction that occurred on Friday, October 6th. The shares were sold at an average price of $21.96, for a total value of $1,132,323.48. Following the completion of the sale, the chief executive officer now directly owns 89,131 shares in the company, valued at $1,957,316.76. The disclosure for this sale can be found here. Insiders have sold a total of 79,932 shares of company stock valued at $1,833,547 over the last ninety days. Company insiders own 27.50% of the company’s stock.
Institutional Trading of ACADIA Pharmaceuticals
Several institutional investors have recently bought and sold shares of ACAD. Osaic Holdings Inc. boosted its stake in shares of ACADIA Pharmaceuticals by 29.3% in the second quarter. Osaic Holdings Inc. now owns 31,909 shares of the biopharmaceutical company’s stock worth $767,000 after acquiring an additional 7,234 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of ACADIA Pharmaceuticals by 32.6% in the second quarter. Nuveen Asset Management LLC now owns 690,966 shares of the biopharmaceutical company’s stock worth $16,549,000 after acquiring an additional 169,717 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of ACADIA Pharmaceuticals by 26.2% in the second quarter. Alliancebernstein L.P. now owns 192,111 shares of the biopharmaceutical company’s stock worth $4,601,000 after acquiring an additional 39,910 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of ACADIA Pharmaceuticals by 4.3% in the second quarter. Wells Fargo & Company MN now owns 186,957 shares of the biopharmaceutical company’s stock worth $4,478,000 after acquiring an additional 7,730 shares during the last quarter. Finally, Natixis Advisors L.P. boosted its stake in shares of ACADIA Pharmaceuticals by 79.5% in the second quarter. Natixis Advisors L.P. now owns 25,087 shares of the biopharmaceutical company’s stock worth $601,000 after acquiring an additional 11,110 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Read More
- Five stocks we like better than ACADIA Pharmaceuticals
- What are stock market earnings reports?
- The top 3 stocks insiders are selling, but you shouldn’t
- How to Invest in Mining Stocks
- Spirit AeroSystems Goes Airborne After Inking a Boeing Deal
- 3 Fintech Stocks With Good 2021 Prospects
- Simon Property Group’s 7.2% Dividend Has Insiders Buying In Bulk
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
